Browsing by Keyword : Receptors, Estrogen
Showing results 3 to 15 of 15
Pub Year | | Title | AJOU Author(s) |
2002 | | Donor specific response of estrogen and progesterone on cultured human melanocytes. | 강원형, 김완기, 이은소, 임성빈 |
2020 | | Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer | 정용식 |
2022 | | Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer | 강석윤 |
2005 | | Expression of female sex hormone receptors in human middle-ear cholesteatomas. | 박기현, 정연훈 |
2013 | | Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression. | 강석윤, 김장희, 박태준, 임현이, 정용식 |
2021 | | Implications of tamoxifen resistance in palbociclib efficacy for patients with hormone receptor-positive, her2-negative metastatic breast cancer: Subgroup analyses of kcsg-br15-10 (youngpearl) | 강석윤 |
2014 | | MET expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting. | 고영화 |
2004 | | Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. | 방오영, 허균 |
2001 | | Neuroprotective effects of estrogen against beta-amyloid toxicity are mediated by estrogen receptors in cultured neuronal cells. | 김승업, 묵인희, 방오영, 정민환, 허균 |
2019 | | Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial | 강석윤 |
2014 | | Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). | 정용식 |
2014 | | Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. | 고영화 |
2022 | | Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population | 정용식 |
1